Hemostats market seen doubling to $6.06 billion by 2035

The global hemostats market is projected to rise from $3.24 billion in 2025 to $6.06 billion by 2035, according to Market Research Future. Growth is being fueled by more surgeries, older patients, wider anticoagulant use and faster adoption of minimally invasive procedures.

Why it matters: - Hemostats are used to control bleeding in surgery, so market growth tracks procedure volume, patient risk and operating-room technology shifts. - Demand is rising as hospitals handle more elective cases, more older patients and more complex bleeding-control needs. - The forecast points to stronger demand for flowable, powder and laparoscopic-delivery products, not just traditional sponges and pads.

What happened: - Market Research Future projected the global hemostats market will reach $6.06 billion by 2035, up from $3.24 billion in 2025. - The forecast implies a 6.45% compound annual growth rate from 2026 to 2035. - The first forecast year, 2026, is valued at $3.45 billion. - The research also identified North America as the largest regional market with a 39.8% share in 2025. - Asia-Pacific is expected to grow fastest, at an 8.9% CAGR through 2035.

The details: - Surgical volume recovery is a major driver. - The Australian Institute of Health and Welfare recorded 771,600 public-hospital elective surgery admissions in 2023–24, up from 735,500 the year before. - NHS England committed GBP 8.0 billion between 2022 and 2025 to its elective recovery initiative. - Aging populations and anticoagulant use are increasing bleeding risk in surgery. - The World Health Organization estimates 1 in 6 people worldwide will be 60 or older by 2030. - Anticoagulant prescriptions rose by more than 40% between 2019 and 2024 in major European markets. - Minimally invasive and robotic surgery are changing product requirements. - Intuitive Surgical reported roughly 2.68 million da Vinci procedures globally in 2024, up about 17% year over year. - The shift to ambulatory surgical centers is also reshaping buying patterns. - The US Centers for Medicare & Medicaid Services has added hundreds of procedures to the ASC covered list since 2020. - Absorbable hemostats held a 76.5% share in 2025. - Non-absorbable hemostats are forecast to grow at 7.0% CAGR from 2026 to 2035. - Matrix and gel products were the largest formulation segment at $1.11 billion in 2025. - Powders are the fastest-growing formulation. - Sheets and pads held a 26.8% share in 2025. - Sponges are projected to grow at 5.8% CAGR through 2035. - General surgery was the largest application segment with a 31.4% share in 2025. - Cardiovascular surgery was the highest value-per-case segment at $0.73 billion in 2025. - Orthopedic surgery is forecast to grow fastest, at 7.3% CAGR. - Neurological surgery held a 13.2% share in 2025. - Hospitals and clinics accounted for 68.4% of end-user demand in 2025. - Ambulatory surgical centers are expected to grow fastest, at 8.4% CAGR.

Between the lines: - The market is moving toward products that work in narrower access channels and on irregular bleeding surfaces. - Suppliers with laparoscopic delivery systems and smaller pack sizes are better positioned as care shifts to robotic surgery and ambulatory settings. - Price pressure is likely to stay strong in commodity formats, especially in emerging markets. - Concentration remains high, with the top five suppliers holding an estimated 61% to 66% of global revenue. - Regional challengers in China and India compete on price but have limited presence in higher-acuity tenders. - Combined R&D and capacity spending across the top five suppliers exceeded $1.1 billion in 2024.

What's next: - Flowable and powder products are likely to capture more premium demand as surgeons treat diffuse bleeding on organs and other irregular surfaces. - Emerging-market hospital expansion, especially in India, should create new demand over the forecast period. - Trauma and prehospital channels may become more important for suppliers that can meet shelf-stability and extreme-temperature requirements. - Outcome-linked contracting and data services could become a differentiator for suppliers able to show reduced transfusion rates and shorter operating times. - Bioengineered and plant-derived materials may gain share as cost gaps narrow and sourcing concerns persist.

The bottom line: - Hemostats are set for steady, surgery-linked growth through 2035, with the strongest momentum coming from minimally invasive procedures, outpatient care and higher-bleeding-risk patients.